Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

Corporate Breaking News

Home : Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

Apr 02 2019	Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11
OSLO, Norway, April 2, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported today in an oral presentation at TAT11, the 11th...


Source:https://www.prnewswire.com:443/news-releases/nordic-nanovector-promising-results-from-preclinical-studies-with-a-novel-cd37-targeted-alpha-therapy-for-b-cell-tumours-presented-at-tat11-300822527.html

Related News
» BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance » Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results